Viking Therapeutics, Inc. (VKTX)
Stock Price:
$7.36 USD
-0.17 (-2.26%)
Updated Aug 14, 2020 4:00 PM EDT - Market closed
After-hours: $7.48 +0.12 (1.63%) Aug 14, 7:58 PM
Key Info
| Market Cap |
535.50M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-32.44M |
| Shares Out |
72.76M |
| EPS (ttm) |
-0.45 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 14, 2020 |
| Last Price |
$7.36 |
| Previous Close |
$7.53 |
| Change ($) |
-0.17 |
| Change (%) |
-2.26% |
| Day's Open |
7.53 |
| Day's Range |
7.32 - 7.59 |
| Day's Volume |
843,474 |
| 52-Week Range |
3.26 - 8.87 |
More Stats
| Market Cap |
535.50M |
| Enterprise Value |
272.67M |
| Earnings Date (est) |
Nov 5, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
72.76M |
| Float |
56.05M |
| EPS (basic) |
-0.45 |
| EPS (diluted) |
-0.45 |
| FCF / Share |
-0.36 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
11.92M |
| Short Ratio |
8.06 |
| Short % of Float |
18.81% |
| Beta |
2.02 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
2.09 |
| Revenue |
n/a |
| Operating Income |
-37.87M |
| Net Income |
-32.44M |
| Free Cash Flow |
-26.11M |
| Net Cash |
262.83M |
| Net Cash / Share |
3.61 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-8.37% |
| ROE |
-11.79% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (14)
| Buy |
14 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$16.58*
(125.27% upside)
Low
9.00
Current: $7.36
High
28.00
Target: 16.58
*Average 12-month price target from 12 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|
| Revenue | - | - | - | - | - | - | - |
| Operating Income | -32.69 | -26.16 | -19.07 | -13.85 | -12.00 | -23.47 | -0.10 |
| Net Income | -25.78 | -22.06 | -20.58 | -14.73 | -23.40 | -21.88 | -0.15 |
| Shares Outstanding | 71.96 | 57.58 | 25.98 | 16.28 | 6.36 | 4.19 | 2.04 |
| Earnings Per Share | -0.36 | -0.38 | -0.79 | -0.90 | -3.68 | -5.23 | -0.07 |
| Operating Cash Flow | -24.75 | -18.76 | -14.76 | -11.07 | -8.73 | -1.59 | -0.08 |
| Free Cash Flow | -24.75 | -18.76 | -14.76 | -11.07 | -8.73 | -1.59 | -0.08 |
| Cash & Equivalents | 276 | 302 | 20.58 | 13.19 | 14.18 | 0.76 | 0.18 |
| Total Debt | 0.36 | - | 3.45 | 3.27 | 2.15 | 1.57 | 0.28 |
| Net Cash / Debt | 275 | 302 | 17.12 | 9.92 | 12.03 | -0.81 | -0.10 |
| Assets | 284 | 302 | 22.12 | 14.54 | 15.44 | 3.04 | 0.18 |
| Liabilities | 7.14 | 4.56 | 8.66 | 6.49 | 6.71 | 25.17 | 0.43 |
| Book Value | 277 | 298 | 13.46 | 8.04 | 8.72 | -22.13 | -0.25 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Viking Therapeutics, Inc. |
| Country |
United States |
| Employees |
18 |
| CEO |
Brian Lian |
Stock Information
| Ticker Symbol |
VKTX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: VKTX |
| IPO Date |
April 29, 2015 |
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase 2b clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis. The company's lead drug candidate also includes VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery. It is also developing VK0612, an orally available Phase 2b-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta for X-linked adrenoleukodystrophy. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.